Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Go back to Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress| (NASDAQ: TVTX) | Delayed: 52.04 +3.13 (6.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.91 | 52 Week High | $ | |||
| Open | $49.10 | 52 Week Low | $ | |||
| Day High | $52.72 | P/E | N/A | |||
| Day Low | $48.98 | EPS | $ | |||
| Volume | 2,389,045 | |||||
